EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin By Ogkologos - August 18, 2025 191 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Honeybee Venom May Be the Next Treatment for Aggressive Breast Cancer September 2, 2020 Cancer Research UK reports record levels of investment in its spinouts August 24, 2021 Quality of Life Is Maintained with First-line Nivolumab Plus Ipilimumab in... December 10, 2020 Determining Fluid Requirements March 26, 2021 Load more HOT NEWS Scientists uncover how incurable skin cancer resists treatment at the end... Adding Durvalumab to First-Line Platinum-Based Chemotherapy Followed by Maintenance Durvalumab With... 18-Year-Old Jaguar at Akron Zoo Diagnosed with Breast Cancer FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with...
